IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial-Reference-Cited by-同舟云学术

IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial

Published:2019-09 Issue:1 Volume:1 Page:e35-e43
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Xu Huji,Li Zhijun,Wu Jian,Xing Qian,Shi Guixiu,Li Juan,Liu Xu,Wu Lijun,Li Xiaomei,Tan Wenfeng,He Dongyi,Bi Liqi,Li Hongbin,Xiao Zhengyu,Shuai Zongwen,Li Xiaoxia,Wang Yongfu,Luo Li,Zheng Yi,Xiao Weiguo,Wu Xin,Zhou Ling,Li Ting,Qian Lei,Zhou Hui,Lu Shujie,Zheng Shirui,Xiong Yan,Wang Xiong,Wang Yanqi,Wu Xinjiang

Funder

“Significant New Drugs Development”

National Natural Science Foundation of China

China Ministry of Science and Technology

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference31 articles.

1. Ankylosing spondylitis;Braun;Lancet,2007

2. Pathogenesis of ankylosing spondylitis;Tam;Nat Rev Rheumatol,2010

3. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial;van der Heijde;Arthritis Rheum,2006